HD-X platform offered in a regulated environment for the first time in Europe by LGC
UK based bioanalytical CRO, LGC (Cambridge, UK), have announced the launch of its Quanterix Simoa HD-X automated analyzer at its GxP accredited lab in Fordham, near Cambridge, UK. In doing so, LGC have become the first bioanalytical CRO in Europe to offer the flagship Quanterix platform in a regulated environment.
The Simoa HD-X, unveiled at the 2019 BIO International Convention (3–6 June, Philadelphia; PA, USA), is Quanterix’s latest flagship bead-based immunoassay instrument model, offering extremely high PK/PD assay sensitivity and precision using a digital form of ELISA. It does this by trapping and sealing individual immunocomplexes on paramagnetic beads in thousands of femtolitre-scale wells.
Rachel Green, Operations Director at LGC, explained: “The Quanterix HD-X system has enhanced our capability to develop novel, high sensitivity and high throughput immunoassays. The increase in sensitivity that the HD-X offers is between 50–1000 times, compared with other conventional assay platforms – combining this with its automated and multiplexing capabilities, this platform could prove invaluable in helping our customers with early PK/PD decision making, translating into long term efficiencies in their drug development programs.”
Kevin Hrusovsky, Chairman and CEO (Quanterix; MA, USA) added: “We believe Simoa can dramatically accelerate drug development, delivering insights that can help make drugs less toxic and more efficacious, and is an ideal tool combined with LGC’s industry-leading bioanalytical capabilities.”
